Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Many different definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria are being used in the medical literature to characterize the different patterns of resistance found in healthcare-associated, antimicrobial-resistant bacteria. A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp., Enterobacteriaceae (other than Salmonella and Shigella), Pseudomonas aeruginosa and Acinetobacter spp., all bacteria often responsible for healthcare-associated infections and prone to multidrug resistance. Epidemiologically significant antimicrobial categories were constructed for each bacterium. Lists of antimicrobial categories proposed for antimicrobial susceptibility testing were created using documents and breakpoints from the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the United States Food and Drug Administration (FDA). MDR was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) and PDR was defined as non-susceptibility to all agents in all antimicrobial categories. To ensure correct application of these definitions, bacterial isolates should be tested against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of results should be avoided.

[1]  A. Hidrón,et al.  Multidrug Resistance among Gram-Negative Pathogens That Caused Healthcare-Associated Infections Reported to the National Healthcare Safety Network, 2006–2008 , 2010, Infection Control & Hospital Epidemiology.

[2]  Y. Carmeli,et al.  Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  Bala Hota,et al.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Unemo,et al.  Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae , 2009, Expert review of anti-infective therapy.

[5]  K. Ko,et al.  Extreme Drug Resistance in Acinetobacter baumannii Infections in Intensive Care Units, South Korea , 2009, Emerging infectious diseases.

[6]  F. Aarestrup,et al.  WHO Global Salm-Surv External Quality Assurance System for Serotyping of Salmonella Isolates from 2000 to 2007 , 2009, Journal of Clinical Microbiology.

[7]  D. Paterson,et al.  Extensively Drug-Resistant Acinetobacter baumannii , 2009, Emerging infectious diseases.

[8]  S. Gautam,et al.  Colonization with multidrug-resistant gram-negative bacteria: prolonged duration and frequent cocolonization. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Richter,et al.  Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. MacGowan,et al.  Clinical implications of antimicrobial resistance for therapy. , 2008, The Journal of antimicrobial chemotherapy.

[12]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[13]  C. Parry,et al.  Antimicrobial resistance in typhoidal and nontyphoidal salmonellae , 2008, Current opinion in infectious diseases.

[14]  D. Warren,et al.  A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  R. Weinstein,et al.  Recommendations For Metrics For Multidrug-Resistant Organisms In Healthcare Settings: SHEA/HICPAC Position Paper , 2008, Infection Control & Hospital Epidemiology.

[16]  C. Feldman,et al.  Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer. , 2008, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[17]  L. Chan,et al.  Interactions of antimicrobial compounds with cross-linking agents of alginate dressings. , 2008, The Journal of antimicrobial chemotherapy.

[18]  M. Falagas,et al.  Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  K. Laupland,et al.  Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern , 2008 .

[20]  D. Sahm,et al.  Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. , 2008, Diagnostic microbiology and infectious disease.

[21]  M. Jackson,et al.  Management of multidrug-resistant organisms in health care settings, 2006. , 2007, American journal of infection control.

[22]  D. Paterson,et al.  A step closer to extreme drug resistance (XDR) in gram-negative bacilli. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Rhee,et al.  Molecular epidemiology of community-associated antimicrobial-resistant Staphylococcus aureus in Seoul, Korea (2003): pervasiveness of multidrug-resistant SCCmec type II methicillin-resistant S. aureus. , 2007, Microbial drug resistance.

[24]  W. Chie,et al.  Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. , 2007, Diagnostic microbiology and infectious disease.

[25]  M. Falagas,et al.  The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. , 2006, Journal of medical microbiology.

[26]  D. Paterson The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  R. Bonomo,et al.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  C. Woods,et al.  Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  J. Mcgowan Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. , 2006, The American journal of medicine.

[30]  D. Anderson,et al.  Predictors of Mortality in Patients with Bloodstream Infection Due to Ceftazidime-Resistant Klebsiella pneumoniae , 2006, Antimicrobial Agents and Chemotherapy.

[31]  E. Gotuzzo,et al.  Oxacillin-Resistant and Multidrug-Resistant Staphylococcus aureus in Lima, Peru , 2006, Infection Control & Hospital Epidemiology.

[32]  G. Rossolini,et al.  Nosocomial Outbreak Caused by Multidrug-Resistant Pseudomonas aeruginosa Producing IMP-13 Metallo-β-Lactamase , 2005, Journal of Clinical Microbiology.

[33]  C. Schultsz,et al.  Endemic Multidrug-Resistant Pseudomonas aeruginosa in Critically Ill Patients , 2004, Infection Control & Hospital Epidemiology.

[34]  R. MacLaren,et al.  Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. , 2004, The Journal of hospital infection.

[35]  Chong-Jen Yu,et al.  Dissemination of a Clone of Unusual Phenotype of Pandrug-Resistant Acinetobacter baumannii at a University Hospital in Taiwan , 2004, Journal of Clinical Microbiology.

[36]  D. Hughes,et al.  Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections , 2003, Antimicrobial Agents and Chemotherapy.

[37]  Pan‐Chyr Yang,et al.  Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. , 2003, Journal of the Formosan Medical Association = Taiwan yi zhi.

[38]  H. Goossens Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[39]  Ronald N. Jones,et al.  Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). , 2003, The Journal of antimicrobial chemotherapy.

[40]  A. Bush,et al.  Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: Natural history and implications for segregation , 2003, Pediatric pulmonology.

[41]  J. Karlowsky,et al.  Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. , 2003, The Journal of antimicrobial chemotherapy.

[42]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  R. Leclercq,et al.  Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  R. Masterton,et al.  Determining the value of antimicrobial surveillance programs. , 2001, Diagnostic microbiology and infectious disease.

[45]  V. Dubois,et al.  Nosocomial Outbreak Due to a Multiresistant Strain of Pseudomonas aeruginosa P12: Efficacy of Cefepime-Amikacin Therapy and Analysis of β-Lactam Resistance , 2001, Journal of Clinical Microbiology.

[46]  S. Aaron,et al.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. , 2000, American journal of respiratory and critical care medicine.

[47]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[48]  D. Livermore,et al.  Epidemiology of antibiotic resistance , 2000, Intensive Care Medicine.